Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
With
National Council of Science and Technology, Mexico
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Systemic Lupus Erythematosus according to the American College of Rheumatology Criteria
On a daily dose of prednisone of ≥ 15 mg/d or equivalent, and that are expected to remain on the this dose for at least 1 month.
Have signed an informed consent
You may not be if
Absolute contraindication to receive TMP-SMX (known allergy to TMP-SMX or sulfa drugs; TMP-SMX induced thrombocytopenia)
Received TMP-SMX treatment in the previous month
Creatinine clearance \<30ml/min/m2
Chronic viral infection (Hepatitis C virus, Hepatitis B virus, Human immunodeficiency virus)
Malignant neoplasm, except for skin neoplasm
Primary immune deficiencies
Solid organ or hematopoietic stem cell transplant recipients
Pregnancy or Breastfeeding
Current active infection, except mild active infections that to the judgement of the primary investigator do not jeopardize the study outcomes (e.g. tinea).
Uncontrolled chronic infection (e.g. tuberculosis- intensive phase treatment), except mild active chronic infections that to the judgement of the primary investigator do not jeopardize the study outcomes (e.g. onychomycosis).
Controlled chronic infection, that needs to be treated or prevented with TMP-SMX.
Patients participating in another research study that to the judgement of the principal investigator could jeopardize the safety or efficacy of the study drug.
Clareo Health | Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous
